OR WAIT null SECS
August 28, 2020
AbCellera’s recent acquisition of the OrthoMab bispecific platform is expected to accelerate antibody product development.
In the study, GigaGen presents a novel technology for producing a new class of drug, recombinant hyperimmunes, that may potentially generate new COVID-19 therapies.
August 20, 2020
CARBOGEN AMCIS has announced significant investments to increase manufacturing capacity in Switzerland and France.
August 13, 2020
Atomwise’s technology, AtomNet, works to eliminate the barriers of physical screening for small molecule drug discovery.
August 10, 2020
Citing undisclosed allegations against Kodak, the DFC placed a hold on a potential $765 million loan to launch US-based API manufacturing.
August 03, 2020
The COVID-19 pandemic has raised several questions about the safety of the pharmaceutical materials supply chain. Is onshoring the answer?
Understanding and overcoming excipient variation are crucial for successful continuous processes.
August 02, 2020
The early success seen on the market for approved cell and gene therapies poses both technical and manufacturing challenges for pipeline candidates on the road to commercialization.
July 08, 2020
CordenPharma added a 3000-L solid-phase peptide synthesis vessel to its GMP API facility in Boulder, CO.
VAR2 Pharmaceuticals has been selected for its development of a drug-conjugated malaria protein that potentially selectively binds to most human tumor types.
